Even before the financial crash of 2008, investors have long had a penchant for seeking out that future gold mine hidden like a jewel in a thicket.
As the investment bubble inflated amid clamorous markets, many medical devices, procedures and tests took medically-related equities to new heights. But who could have guessed that a 16-year-old Brit would change the world of medical diagnostics, with a test that costs just pennies to conduct?
Jack Andraka, an ambitious teen in the U.K., has developed a promising method to conduct a rapid and extremely low-cost test — one that detects cancer at the earliest stages, which no present-day conventional tests can do. It’s a dipstick diagnostic procedure and the target is to find those “bio markers” that reveal whether the body’s cellular division has gone astray.
During the run up to the world-wide fiscal crisis, culminating in the historic failure of Lehman Brothers, medical devices and patented diagnostic tests ushered in a stock-market bubble that led to a world-wide fiscal crisis. Yet, such miraculous breakthroughs are just one reason investors find medical diagnostics and treatments so compelling. The stakes are often high, but the allure of achieving that long-sought miracle cure entices investors to include medically-related stocks in their portfolios.
Options trades allow an investor to potentially cash in on these emerging opportunities, but knowledge is worth its weight in gold when it comes to playing the markets. If you’re interested in learning more about options trading, our self-paced DVD course can get you on your way.